Engineered to kill
How Nkarta’s approach to engineering NK cells stands out from the pack
Nkarta Inc. is betting that boosting NK cells’ intrinsic ability to discriminate between cancer and healthy cells will increase their efficacy as anti-cancer agents and lower their risk of toxicity compared with the more common tactic of adding in chimeric antigen receptors.
The company was formed to develop technology from scientific founder Dario Campana, and has been incubating in Johnson & Johnson’s South San Francisco JLABS site since 2015, with undisclosed funding from SR One, New Enterprise Associates and Novo Ventures...